吉西他滨和奥沙利铂联合阿帕替尼治疗胆囊癌的疗效观察

目的分析吉西他滨和奥沙利铂联合阿帕替尼治疗胆囊癌的疗效。方法74例胆囊癌患者,根据治疗方法不同分为对照组和研究组,每组37例。对照组患者接受吉西他滨联合奥沙利铂治疗,研究组患者在对照组基础上接受阿帕替尼治疗。对比两组患者的治疗效果、治疗前与治疗1个月后血清肿瘤标志物血管内皮生长因子(VEGF)、癌胚抗原(CEA)、可溶性白细胞介素-2受体(sIL-2R)、Dickkopf-1]水平。结果研究组患者疾病控制率为94.59%,高于对照组的75.68%,差异具有统计学意义(P<0.05)。治疗1个月后,两组患者的VEGF、CEA、sIL-2R、Dickkopf-1水平均较本组治疗前降低,且研究组患者VEGF(265.25±82.41)ng/ml、CEA(15.65±6.75)ng/ml、sIL-2R(528.49±95.51)U/ml、Dickkopf-1(1.21±0.32)ng/ml低于对照组的(358.37±79.52)ng/ml、(21.61±9.45)ng/ml、(635.31±102.67)U/ml、(1.65±0.39)ng/ml,差异具有统计学意义(P<0.05)。结论在胆囊癌的治疗中,采用吉西他滨和奥沙利铂联合阿帕替尼治疗能有效控制患者的病情进展。

Observation on efficacy of gemcitabine and oxaliplatin combined with apatinib in the treatment of gallbladder cancer

Objective To analyze the efficacy of gemcitabine and oxaliplatin combined with apatinib in the treatment of gallbladder cancer.Methods A total of 74 patients with gallbladder cancer were divided into control group and research group according to different treatment methods,with 37 cases in each group.Patients in the control group received gemcitabine combined with oxaliplatin,and patients in the research group received apatinib treatment on the basis of the control group.The therapeutic effect,and serum tumor markersvascular endothelial growth factor(VEGF),carcinoembryonic antigen(CEA),soluble interleukin-2 receptor(sIL-2R),Dickkopf-1]level of the two groups were compared.Results The disease control rate in the research group was 94.59%,which was higher than 75.68%in the control group,and the difference was statistically significant(P<0.05).After 1 month of treatment,the levels of VEGF,CEA,sIL-2R,and Dickkopf-1 of the two groups were lower than those of this group before treatment;the VEGF(265.25±82.41)ng/ml,CEA(15.65±6.75)ng/ml,sIL-2R(528.49±95.51)U/ml,Dickkopf-1(1.21±0.32)ng/ml of the research group were lower than(358.37±79.52)ng/ml,(21.61±9.45)ng/ml,(635.31±102.67)U/ml,(1.65±0.39)ng/ml of the control group;all the differences were statistically significant(P<0.05).Conclusion In the treatment of gallbladder cancer,gemcitabine and oxaliplatin combined with apatinib can effectively control the disease progression of patients.